A single centre experience with clinical use of Neria™ Guard as mode of pain and distress management in the administration of emicizumab in children

1. Oldenburg J, Mahlangu JN, Bujan W, et al. The effect of emicizumab prophylaxis on health-related outcomes in persons with haemophilia A with inhibitors: HAVEN 1 Study. Haemophilia 2019; 25: 33-44. doi: 10.1111/hae.13618 Oldenburg J Mahlangu JN Bujan W The effect of emicizumab prophylaxis on health-related outcomes in persons with haemophilia A with inhibitors: HAVEN 1 Study . Haemophilia 2019 ; 25 : 33 – 44 . doi: 10.1111/hae.13618 Open DOISearch in Google Scholar

2. Mancuso ME, Mahlangu J, Sidonio R Jr, et al. Health-related quality of life and caregiver burden of emicizumab in children with haemophilia A and factor VIII inhibitors-Results from the HAVEN 2 study. Haemophilia 2020; 26(6): 1009-1018. doi: 10.1111/hae.14183. Mancuso ME Mahlangu J Sidonio R Jr Health-related quality of life and caregiver burden of emicizumab in children with haemophilia A and factor VIII inhibitors-Results from the HAVEN 2 study . Haemophilia 2020 ; 26 ( 6 ): 1009 – 1018 . doi: 10.1111/hae.14183 . Open DOISearch in Google Scholar

3. Skinner MW, Négrier C, Paz-Priel I, et al. The effect of emicizumab prophylaxis on long-term, self-reported physical health in persons with haemophilia A without Factor VIII inhibitors in the HAVEN 3 and HAVEN 4 studies. Haemophilia 2021; 27: 854-865. doi: 10.1111/hae.14363. Skinner MW Négrier C Paz-Priel I The effect of emicizumab prophylaxis on long-term, self-reported physical health in persons with haemophilia A without Factor VIII inhibitors in the HAVEN 3 and HAVEN 4 studies . Haemophilia 2021 ; 27 : 854 – 865 . doi: 10.1111/hae.14363 . Open DOISearch in Google Scholar

4. Marro M, Petit AF, Céline Falaise M, et al. Early changes in bleeding perception and quality of life in children and adolescents receiving emicizumab prophylaxis for severe haemophilia A without inhibitor. Haemophilia 2023; 29(1): 397-400. doi: 10.1111/hae.14724. Marro M Petit AF Céline Falaise M Early changes in bleeding perception and quality of life in children and adolescents receiving emicizumab prophylaxis for severe haemophilia A without inhibitor . Haemophilia 2023 ; 29 ( 1 ): 397 – 400 . doi: 10.1111/hae.14724 . Open DOISearch in Google Scholar

5. Oldenburg J, Mahlangu N J, Kim B, et al. Emicizumab prophylaxis in hemophilia A with inhibitors. N Engl J Med 2017; 377: 809-818. doi: 10.1056/NEJMoa1703068. Oldenburg J Mahlangu N J Kim B Emicizumab prophylaxis in hemophilia A with inhibitors . N Engl J Med 2017 ; 377 : 809 – 818 . doi: 10.1056/NEJMoa1703068 . Open DOISearch in Google Scholar

6. Young G, Liesner R, Chang T, et al. A multicenter, open-label phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors. Blood 2019; 134(24): 2127-2138. doi: 10.1182/blood.2019001869. Young G Liesner R Chang T A multicenter, open-label phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors . Blood 2019 ; 134 ( 24 ): 2127 – 2138 . doi: 10.1182/blood.2019001869 . Open DOISearch in Google Scholar

7. Mahlangu J, Oldenburg J, Paz-Priel I, et al. Emicizumab prophylaxis in patients who have hemophilia A without inhibitors. N Engl J Med 2018; 379: 811-822. doi: 10.1056/NEJMoa1803550. Mahlangu J Oldenburg J Paz-Priel I Emicizumab prophylaxis in patients who have hemophilia A without inhibitors . N Engl J Med 2018 ; 379 : 811 – 822 . doi: 10.1056/NEJMoa1803550 . Open DOISearch in Google Scholar

8. Pipe SW, Shima M, Lehle FM, et al. Emicizumab prophylaxis in patients who have hemophilia A without Inhibitors. Efficacy, safety, and pharmacokinetics of Emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomized phase 3 study. Lancet Haematol 2019; 6(6): e295-e305. doi: 10.1016/S2352-3026(19)30054-7. Pipe SW Shima M Lehle FM Emicizumab prophylaxis in patients who have hemophilia A without Inhibitors. Efficacy, safety, and pharmacokinetics of Emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomized phase 3 study . Lancet Haematol 2019 ; 6 ( 6 ): e295 – e305 . doi: 10.1016/S2352-3026(19)30054-7 . Open DOISearch in Google Scholar

9. Yang R, Wang S, Wang X, et al. Prophylactic emicizumab for hemophilia A in the Asia-Pacific region: A randomized study. Res Pract Thromb Haemost 2022; 6(2): e12670. doi: 10.1002/rth2.12670. Yang R Wang S Wang X Prophylactic emicizumab for hemophilia A in the Asia-Pacific region: A randomized study . Res Pract Thromb Haemost 2022 ; 6 ( 2 ): e12670 . doi: 10.1002/rth2.12670 . Open DOISearch in Google Scholar

10. Negrier C, Mahlangu J, Lehle M, et al. Emicizumab in people with moderate or mild haemophilia A (HAVEN 6): a multicentre, open-label, single-arm phase 3 study. Lancet Haematol 2023; 10(3): e168-e177. doi: 10.1016/S2352-3026(22)00377-5. Negrier C Mahlangu J Lehle M Emicizumab in people with moderate or mild haemophilia A (HAVEN 6): a multicentre, open-label, single-arm phase 3 study . Lancet Haematol 2023 ; 10 ( 3 ): e168 – e177 . doi: 10.1016/S2352-3026(22)00377-5 . Open DOISearch in Google Scholar

11. Pipe SW, Collins P, Dhalluin C, et al. Emicizumab prophylaxis for the treatment of infants with severe hemophilia A without factor VIII inhibitors: Results from the interim analysis of the HAVEN 7 Study. Blood 2023; 143(14): 1355-1364. doi: 10.1182/blood.2023021832. Pipe SW Collins P Dhalluin C Emicizumab prophylaxis for the treatment of infants with severe hemophilia A without factor VIII inhibitors: Results from the interim analysis of the HAVEN 7 Study . Blood 2023 ; 143 ( 14 ): 1355 – 1364 . doi: 10.1182/blood.2023021832 . Open DOISearch in Google Scholar

12. Convatec. Product data sheet: Neria™ Guard. Available from https://marketingworld.convatec.com/Api/PresentationMediaSource?applicationToken=dc038e44b0b0ee4d8616f7b6880b24551bfecf237645a04fb5b76ab792a36858&itemId=43c1f37d-7688-484a-a021-f0b09a3010a3&contentLanguageId=en-GB&forceDownload=true(accessed May 2024). Convatec . Product data sheet: Neria™ Guard . Available from https://marketingworld.convatec.com/Api/PresentationMediaSource?applicationToken=dc038e44b0b0ee4d8616f7b6880b24551bfecf237645a04fb5b76ab792a36858&itemId=43c1f37d-7688-484a-a021-f0b09a3010a3&contentLanguageId=en-GB&forceDownload=true (accessed May 2024 ). Search in Google Scholar

13. Renfrew CW, JM, Fee JP. A qualitative investigation into the physical stability of polypropylene and polyethylene in liquid isoflurane and sevoflurane. Anaesthesia 2000; 55(8): 793-7. doi: 10.1046/j.1365-2044.2000.01365.x. Renfrew CW JM, Fee JP. A qualitative investigation into the physical stability of polypropylene and polyethylene in liquid isoflurane and sevoflurane . Anaesthesia 2000 ; 55 ( 8 ): 793 – 7 . doi: 10.1046/j.1365-2044.2000.01365.x . Open DOISearch in Google Scholar

14. Roche. Core data sheet: Hemlibra (Emicizumab R05534262)-version 11.0. Available from https://assets.roche.com/f/184741/x/8a04a45f66/hemlibra.pdf(accessed May 2024]. Roche . Core data sheet: Hemlibra (Emicizumab R05534262)-version 11.0 . Available from https://assets.roche.com/f/184741/x/8a04a45f66/hemlibra.pdf (accessed May 2024 ]. Search in Google Scholar

15. Ciavarella A, Arcudi S, Biguzzi E, et al Which level of emicizumab is necessary for a good hemostasis? Blood 2021 138 (Suppl 1): 4247. doi: 10.1182/blood-2021-150627. Ciavarella A Arcudi S Biguzzi E Which level of emicizumab is necessary for a good hemostasis? Blood 2021 138 ( Suppl 1 ): 4247 . doi: 10.1182/blood-2021-150627 . Open DOISearch in Google Scholar

16. Haverman L, Van Oesr H, Limperg P, et al: Development and validation of the distress thermometer for parents of a chronically ill child. J Pediatr 2013; 163(4): 1140-1146.e2. doi: 10.1016/j.jpeds.2013.06.011. Haverman L Van Oesr H Limperg P Development and validation of the distress thermometer for parents of a chronically ill child . J Pediatr 2013 ; 163 ( 4 ): 1140 – 1146 . e2 . doi: 10.1016/j.jpeds.2013.06.011 . Open DOISearch in Google Scholar

17. Friberg Birkedal M. Nursing challenges and strategies with emicizumab – outcome of survey. Oral presentation, Allied Health Professionals Day, 17th Annual Congress of the European Association for Haemophilia and Allied Disorders, 6 February 2024. Friberg Birkedal M. Nursing challenges and strategies with emicizumab-outcome of survey . Oral presentation, Allied Health Professionals Day, 17th Annual Congress of the European Association for Haemophilia and Allied Disorders , 6 February 2024 . Search in Google Scholar

18. Srivastava A, Santagostino E, Dougall A, et al. WFH Guidelines for the Management of Hemophilia, 3rd edition. Haemophilia 2020: 26(Suppl 6): 1-158. doi: 10.1111/hae.14046. Srivastava A Santagostino E Dougall A WFH Guidelines for the Management of Hemophilia , 3rd edition. Haemophilia 2020 : 26 ( Suppl 6 ): 1 – 158 . doi: 10.1111/hae.14046 . Open DOISearch in Google Scholar

19. Kruis IC, Driessens MH. Pain while injecting emicizumab predominant in children, a report of Dutch patient experiences. Haemophilia 2023; 29(2): 689-691. doi: 10.1111/hae.14757. Kruis IC Driessens MH. Pain while injecting emicizumab predominant in children, a report of Dutch patient experiences . Haemophilia 2023 ; 29 ( 2 ): 689 – 691 . doi: 10.1111/hae.14757 . Open DOISearch in Google Scholar

20. Lombard B. Caregivers blinded by the care. A qualitative study of physical restraint in pediatric care. Nurs Ethics 2020; 27(1): 230-246. doi: 10.1177/0969733019833128. Lombard B. Caregivers blinded by the care. A qualitative study of physical restraint in pediatric care . Nurs Ethics 2020 ; 27 ( 1 ): 230 – 246 . doi: 10.1177/0969733019833128 . Open DOISearch in Google Scholar

21. Taddio A, Chambers CT, Halperin SA, et al. Inadequate pain management during childhood immunizations: the nerve of it. Clin Ther 2009: 31 Suppl 2: S152-67. doi: 10.1016/j. clinthera.2009.07.022. Taddio A Chambers CT Halperin SA Inadequate pain management during childhood immunizations: the nerve of it . Clin Ther 2009 : 31 Suppl 2 : S152 – 67 . doi: 10.1016/j.clinthera.2009.07.022 . Open DOISearch in Google Scholar

22. Donners AAMT, van der Zwet K, Rademaker CMA, Egberts TCG, Schutgens REG, Fischer. The efficacy of the entirevial dosing of emicizumab: Real-world evidence on plasma concentrations, bleeds, and drug waste. Res Pract Thromb Haemost 2023; 7(2): 100074. doi: 10.1016/j.rpth.2023.100074. Donners AAMT van der Zwet K Rademaker CMA Egberts TCG Schutgens REG Fischer The efficacy of the entirevial dosing of emicizumab: Real-world evidence on plasma concentrations, bleeds, and drug waste . Res Pract Thromb Haemost 2023 ; 7 ( 2 ): 100074 . doi: 10.1016/j.rpth.2023.100074 . Open DOISearch in Google Scholar